These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39047248)

  • 1. Anti-CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE.
    Li M; Zhang Y; Jiang N; Ning C; Wang Q; Xu D; Wang Z; Lv L; Zhou D; Zeng X
    N Engl J Med; 2024 Jul; 391(4):376-378. PubMed ID: 39047248
    [No Abstract]   [Full Text] [Related]  

  • 2. Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production.
    Dingfelder J; Aigner M; Taubmann J; Minopoulou I; Park S; Kaplan CD; Cheng JK; Van Blarcom T; Schett G; Mackensen A; Lutzny-Geier G
    Transplant Cell Ther; 2024 Jun; 30(6):582.e1-582.e10. PubMed ID: 38548226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial.
    Wang W; He S; Zhang W; Zhang H; DeStefano VM; Wada M; Pinz K; Deener G; Shah D; Hagag N; Wang M; Hong M; Zeng R; Lan T; Ma Y; Li F; Liang Y; Guo Z; Zou C; Wang M; Ding L; Ma Y; Yuan Y
    Ann Rheum Dis; 2024 Sep; 83(10):1304-1314. PubMed ID: 38777376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T-Cell Therapy in Autoimmune Disease.
    Howard JF; Vu T; Mozaffar T
    N Engl J Med; 2024 May; 390(17):1629-1631. PubMed ID: 38692299
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
    Mackensen A; Müller F; Mougiakakos D; Böltz S; Wilhelm A; Aigner M; Völkl S; Simon D; Kleyer A; Munoz L; Kretschmann S; Kharboutli S; Gary R; Reimann H; Rösler W; Uderhardt S; Bang H; Herrmann M; Ekici AB; Buettner C; Habenicht KM; Winkler TH; Krönke G; Schett G
    Nat Med; 2022 Oct; 28(10):2124-2132. PubMed ID: 36109639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T-Cell Therapy in Autoimmune Disease.
    Merkt W; Lorenz HM; Schmitt M
    N Engl J Med; 2024 May; 390(17):1628-1629. PubMed ID: 38692297
    [No Abstract]   [Full Text] [Related]  

  • 7. CAR T-Cell Therapy in Autoimmune Disease.
    De Benedetti F; Diomedi Camassei F; Locatelli F
    N Engl J Med; 2024 May; 390(17):1629. PubMed ID: 38692298
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful treatment of refractory immune thrombocytopenia with anti-CD20 antibody in a patient with systemic lupus erythematosus.
    Lee JW; Kim HA; Sung JM; Suh CH
    Lupus; 2010 Feb; 19(2):227-8. PubMed ID: 19884220
    [No Abstract]   [Full Text] [Related]  

  • 9. Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases.
    Lyu X; Gupta L; Tholouli E; Chinoy H
    Rheumatology (Oxford); 2024 May; 63(5):1206-1216. PubMed ID: 37982747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.
    Mougiakakos D; Krönke G; Völkl S; Kretschmann S; Aigner M; Kharboutli S; Böltz S; Manger B; Mackensen A; Schett G
    N Engl J Med; 2021 Aug; 385(6):567-569. PubMed ID: 34347960
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond CD19 CAR-T cells in lymphoma.
    Leung WK; Ayanambakkam A; Heslop HE; Hill LC
    Curr Opin Immunol; 2022 Feb; 74():46-52. PubMed ID: 34800921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
    Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
    Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
    Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
    Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview.
    Abdalhadi HM; Chatham WW; Alduraibi FK
    Int J Mol Sci; 2024 Sep; 25(19):. PubMed ID: 39408836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE.
    Wilhelm A; Chambers D; Müller F; Bozec A; Grieshaber-Bouyer R; Winkler T; Mougiakakos D; Mackensen A; Schett G; Krönke G
    JCI Insight; 2024 May; 9(12):. PubMed ID: 38722688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
    Srour SA; Singh H; McCarty J; de Groot E; Huls H; Rondon G; Qazilbash M; Ciurea S; Bardelli G; Buck J; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Wierda WG; Kantarjian H; Champlin RE; Cooper LJ; Kebriaei P
    Blood; 2020 Mar; 135(11):862-865. PubMed ID: 31961918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.